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M A J O R A R T I C L E
Oral Polio Vaccination and Hospital Admissions With
Non-Polio Infections in Denmark: Nationwide
Retrospective Cohort Study
Signe Sørup,1 Lone G. Stensballe,1,2 Tyra G. Krause,3 Peter Aaby,1,4 Christine S. Benn,1,4,5 and Henrik Ravn1,4,5
1Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, 2The Child & Adolescent Clinic, Rigshospitalet, and 3Department of Infectious Disease Epidemiology,
Statens Serum Institut, Copenhagen, Denmark; 4Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; and 5OPEN, Institute of Clinical Research, University of Southern Denmark and Odense
University Hospital
Background. Live vaccines may have nonspeciﬁc beneﬁcial effects on morbidity and mortality. This study examines whether
children who had the live-attenuated oral polio vaccine (OPV) as the most recent vaccine had a different rate of admissions for
infectious diseases than children with inactivated diphtheria-tetanus-pertussis-polio-Haemophilus inﬂuenzae type b vaccine
(DTaP-IPV-Hib) or live measles-mumps-rubella vaccine (MMR) as their most recent vaccine.
Methods. A nationwide, register-based, retrospective cohort study of 137 403 Danish children born 1997–1999, who had re-
ceived 3 doses of DTaP-IPV-Hib, were observed from 24 months (ﬁrst OPV dose) to 36 months of age.
Results. Oral polio vaccine was associated with a lower rate of admissions with any type of non-polio infection compared with
DTaP-IPV-Hib as most recent vaccine (adjusted incidence rate ratio [IRR], 0.85; 95% conﬁdence interval [CI], .77–.95). The asso-
ciation was separately signiﬁcant for admissions with lower respiratory infections (adjusted IRR, 0.73; 95% CI, .61–.87). The admis-
sion rates did not differ for OPV versus MMR.
Conclusions. Like MMR, OPV was associated with fewer admissions for lower respiratory infections than having DTaP-IPV-Hib
as the most recent vaccination. Because OPV is now being phased-out globally, further studies of the potential beneﬁcial nonspeciﬁc
effects of OPV are warranted.
Keywords. heterologous immunity; immunization; nonspeciﬁc effects; nontargeted effects; oral polio vaccination.
There is increasing evidence that vaccines may have not only
speciﬁc effects on the target disease, but also nonspeciﬁc effects
on the incidence of unrelated diseases. The World Health Orga-
nization’s Strategic Advisory Group of Experts on immuniza-
tions (SAGE) recently concluded that further research on
nonspeciﬁc effects of vaccines is needed [1]. This conclusion
was based on a review of Bacille Calmette-Guérin vaccine
(BCG), measles vaccine (MV), and diphtheria, tetanus, and per-
tussis vaccine (DTP), which indicated that the 2 live vaccines,
BCG and MV, were associated with almost a halving of mortal-
ity that was not explained merely by the prevention of the target
diseases [2].
The SAGE review did not include the live oral polio vaccine
(OPV). However, OPV may also have beneﬁcial nonspeciﬁc ef-
fects; previous studies have found that it was associated with
lower child mortality [3–6], lower risk of acute otitis media
[7], and acute respiratory virus infections [8]. Further assess-
ments are important now because the global health community
is planning to replace OPV with inactivated polio vaccine (IPV)
as part of the endgame to eradicate polio virus [9].
Inactivated polio vaccine was introduced in Denmark in 1955
after a polio epidemic, and in 1968 OPV was added to the Dan-
ish vaccination program [10]. For many years, Denmark gave
both IPV in 3 infant doses and OPV at 2, 3, and 4 years of
age. The last case of endogenous polio occurred in 1976, and
the last imported case was in 1983 [10]. In 2001 a phase-out
of OPV began, whereas IPV was maintained [11]. Using data
on vaccination and admissions from national Danish registers,
the potential nonspeciﬁc effects of OPV can be examined for
the birth cohorts 1997–1999, who were born after vaccinations
became registered on their personal identiﬁcation number and
who were still entitled to OPV. In addition to OPV, the recom-
mended vaccination program for these birth cohorts included 3
doses of the inactivated vaccine against diphtheria, tetanus,
acellular pertussis, polio, and Haemophilus inﬂuenzae type b
(DTaP-IPV-Hib) at ages 3, 5, and 12 months, and the live vac-
cine against measles, mumps, and rubella (MMR) at age 15
months.
We tested the hypothesis that OPV was associated with a
lower rate of admissions with any type of non-polio infection
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compared with DTaP-IPV-Hib as most recent vaccine. In addi-
tion, we compared OPV with MMR and with simultaneous ad-
ministration of MMR and OPV. Finally, we examined whether
the associations differed by type of infection and sex as in pre-
vious studies of nonspeciﬁc effects of vaccines [12–15].
METHODS
We included children who were born in Denmark from January
1, 1997 to December 31, 1999 and who were alive and living in
Denmark at 24 months of age. We only included children who
had received DTaP-IPV-Hib3 before 2 years of age to limit the
potential bias related to low vaccination coverage; see Figure 1
for further inclusion criteria. All Danish residents have a unique
personal identiﬁcation number and are registered with date of
birth and whereabouts in the Danish Civil Registration System
[16] enabling identiﬁcation of the cohort. All national Danish
registries record the unique personal identiﬁcation number
[17], which makes it possible to retrieve additional information
about the cohort as described below.
Vaccinations
In Denmark, all recommended childhood vaccinations are non-
compulsory and free of charge. The general practitioners ad-
minister the vaccines and report vaccination information to
the Danish National Health Service Register to receive reim-
bursement [18]. Before 1997, all vaccines were reported using
the personal identiﬁcation number of the parents, but thereafter
they should be reported by the child’s own personal identiﬁca-
tion number. Some childhood vaccines were still registered by
the parents’ personal identiﬁcation number (5.6%); we assigned
these vaccines to the child in the family who was closest to the
recommended age of that vaccine.
Hospital Admissions With Infections
Hospital admissions are free of charge in Denmark. We ob-
tained information on hospital admissions with infections
from the Danish National Patient Register, which includes in-
formation about discharge diagnoses coded according to the
Tenth Revision of the International Classiﬁcation of Diseases
(ICD-10) [19]. We identiﬁed dates of admission and discharge
for all inpatient contacts with primary or secondary discharge
diagnoses of any infection as described previously [14].
Other Register-Based Information
We obtained information on previous admissions, chronic dis-
eases (coded according to Kristensen et al [20]), and emergency
department visits registered as unintentional injuries from the
Danish National Patient Register. Inclusion and follow-up was
deﬁned according to information on births, deaths, and emi-
gration from the Danish Civil Registration System, which also
contains information about a child’s parents, siblings, and
household [16]. Information on maternal smoking during
pregnancy, birth weight, gestational age, and mode of delivery
was obtained from the Danish Medical Birth Register [21].
Information on household equivalence income [22] and mater-
nal education [23] was obtained from Statistics Denmark.
Follow-up
We started follow-up at 2 years of age, when the ﬁrst dose of
OPV was recommended (OPV1). The main focus was the ex-
amination of potential nonspeciﬁc effects of OPV1 compared
Figure 1. Flowchart of inclusion in the study. aFourth dose of inactivated vaccine
against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae
type b (DTaP-IPV-Hib) (N = 3077; 70.3%), second dose of vaccination against mea-
sles, mumps, and rubella (MMR) (N = 605; 13.8%), not recommended combination of
vaccines (N = 358; 8.2%), DTaP-IPV or Hib alone (N = 286; 6.5%), booster dose
against different combinations of diphtheria, tetanus, pertussis (acellular), and
polio (N = 32; 0.7%), or oral polio vaccine (OPV)2 (N = 20; 0.5%). bSome children
had missing information on more than 1 variable. The number of children with miss-
ing information on each variable and in parentheses the percentage among the total
number of children with missing information was as follows: 9732 (65.3%) with
missing information on maternal smoking during pregnancy, 4315 (29.0%) with miss-
ing information on educational level for the female adult in the household, 1775
(11.9%) with missing information on birth weight, 955 (6.4%) with missing informa-
tion on gestational age, 795 (5.3%) with missing information on household income,
276 (1.9%) with missing information on adult composition of the household, 107
(0.7%) with uncertain vaccine allocation for twins or triplets, 102 (0.7%) with miss-
ing information on parental place of birth, 80 (0.5%) with missing information on
caesarean section, 12 (0.1%) with missing information on population density, and
6 (0.0%) with missing information on maternal age at birth of the child. (Note: In-
fectious disease admissions are counted from 24 months of age and until date of
censoring for the children included in the study or until 36 months of age for the
children excluded from the study, because these children did not have a censoring
date.)
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with DTaP-IPV-Hib3 and MMR. Therefore, we did not follow
the children beyond 3 years of age when OPV2 was recom-
mended and a limited number of children had other vaccines
than OPV as the most recent vaccine. Hence, the children
were observed until the earliest of the following events: admin-
istration of other vaccines than DTaP-IPV-Hib, MMR, or
OPV1, 3 years of age, death, emigration, or unknown where-
abouts for the Danish authorities (last date of follow-up was De-
cember 31, 2002). In supplemental analyses, we examined
whether additional doses of OPV compared with OPV1 affected
the rate of admissions for infection between 36 months and 60
months of age (Supplementary Methods).
Statistical Methods
We used Cox regression to estimate the incidence rate ratios
(IRRs) and 95% conﬁdence intervals (CIs) for hospital admis-
sions according to the most recent vaccine (vaccination status
was a time-varying variable). The assumption of proportional
hazards between vaccination types was evaluated by Schoenfeld
residuals, and no violations were detected. All models had age as
the underlying timescale and were stratiﬁed by date of birth to
adjust completely for any effect of age, season, and calendar
year. All admissions with infections were included, so children
may contribute with several admissions. However, because sev-
eral admissions within a short time span may be related to the
same infection, we deﬁned admissions within 14 days after a
previous discharge as the same episode. We used Stata 13 for
both unadjusted analyses and analyses adjusted for the follow-
ing background factors: mother smoking during pregnancy, sex,
birth weight, gestational age, caesarean section, chronic diseas-
es, number of infectious disease admissions before 24 months of
age, admitted to hospital for any cause within the last 30 days,
maternal age at birth of the child, highest educational level for
the female adult in the household, parental place of birth, adults
in the household, income quintiles for the household, other
children in the household, and population density. All statistical
tests were 2-sided, and the threshold for statistical signiﬁcance
was P < .05 and 95% CI for IRRs not overlapping 1.0.
We examined whether the sequence of vaccines was associat-
ed with the rate of admissions with any type of infection. We
performed the analyses separately according to type of infection
and duration of admission. Because a Finish study has reported
that OPV compared with IPV was associated with a 24% (95%
CI, 6%–41%) lower risk of otitis media [7], we tested speciﬁcally
whether there was any association between most recent vaccine
and admissions with otitis media (ICD-10 codes DH65.0–
DH66.9).
Control Outcome
Wewould not expect any association between vaccination status
and emergency department visits after unintentional injury.
Therefore, we performed an analysis with emergency depart-
ment visits after unintentional injury as outcome to examine
whether differential health-seeking behavior could explain asso-
ciations between vaccination status and admissions with
infections.
Interaction
We examined whether the association between the most recent
vaccine and admissions differed according to sex using Wald
test statistics.
Sensitivity Analyses
First, we excluded admissions related to diseases targeted by any
of the included vaccines. Second, vaccines are only registered by
Figure 2. Distribution of the children on the sequence of vaccine groups at 24, 30, and 36 months of age (in parentheses the number of children). (Note: At 24 months of age
137 403 children were included in the study, but at 30 months of age 1303 children had been censored leaving 136 100 children in the study. At 36 months of age another 11 825
children had been censored leaving 124 275 children in the study.) Abbreviations: DTaP-IPV-Hib, inactivated vaccine against diphtheria, tetanus, pertussis (acellular), polio, and
Haemophilus influenzae; MMR, vaccination against measles, mumps, and rubella; OPV, oral polio vaccine.
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the week of vaccination in the Danish National Health Service
Register, and so we coded the date of vaccination as Wednesday
of the speciﬁed week. Therefore, we excluded admissions and
person-time occurring during the week of vaccination to uncov-
er potential misclassiﬁcation of vaccination information. Third,
we repeated the analyses including only children who had all




The study included 137 403 children (Figure 1). Follow-up ended
at age 3 years (N = 124 451; 90.6%), administration of other vac-
cines than MMR or OPV1 (mainly OPV2) (N = 12 876; 9.4%),
migration (N = 64; 0.0%), death (N = 6; 0.0%), and unknown
whereabouts for the Danish authorities (N = 6; 0.0%).
Vaccination
At 24 months of age, 76.4% of the children had received MMR
after DTaP-IPV-Hib3 as the most recent vaccine, and at 36
months of age 65.2% of the children had received OPV1 after
MMR as the most recent vaccine, as expected according to the
recommended vaccination schedule (Figure 2). However, some
children did not follow the recommended vaccination sequence
and received OPV1 after DTaP-IPV-Hib3 or MMR and OPV1
together (Figure 2). The distribution of the most recent vaccine
was statistically signiﬁcantly uneven for most background factors
in a data set of this size, and we adjusted for all background fac-
tors in Supplementary Table 1 in the following analyses.
Admissions With Infections
The study included 6513 admissions with any type of infection
during 135 924 person years of risk, the incidence rate being 4.8
per 100 person years. Figure 3 shows the incidence rates for dif-
ferent sequences of vaccinations. There was no statistically sig-
niﬁcant difference in the rate of admissions with any type of
infection after OPV1 or MMR as the most recent vaccine, no
matter if OPV1 was administered before or after MMR (Fig-
ure 3). Furthermore, the rate of admissions did not differ for
the 2 OPV1 groups, ie, OPV1 after DTaP-IPV-Hib3 or OPV1
after MMR (P equality, .345; Figure 3), or for the 2 MMR
groups, ie, MMR after DTaP-IPV-Hib3 or MMR after OPV1
(P equality, .795; Figure 3). The same applied when admissions
were analyzed by type of infections (Supplementary Figure 1).
Figure 3. Incidence rate and incidence rate ratio (IRR) according to the most recent vaccine and sequence. aThe incidence rate per 100 person years and in brackets the
number of admissions and number of person years. bThe IRRs for the vaccine type the arrow points at relative to the previous vaccine type in the sequence and in brackets
95% confidence interval. Estimated from Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for maternal smoking during
pregnancy, sex, birth weight, gestational age, caesarean section, chronic diseases, number of infectious disease admissions before 24 months of age, admitted to hospital
for any cause within the last 30 days, maternal age at birth of the child, highest educational level for the female adult in the household, parental place of birth, adults in the
household, income quintiles for the household, other children in the household, and population density. cP value from a Wald test of the equality of rates for live vaccine
against measles, mumps, and rubella (MMR) as most recent vaccine in the adjusted model. dP value from a Wald test of the equality of rates for live oral polio vaccine (OPV)
1 as most recent vaccine in the adjusted model. Abbreviations: Adj, adjusted; DTaP-IPV-Hib, inactivated vaccine against diphtheria, tetanus, pertussis (acellular), polio, and
Haemophilus influenzae type b.
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Hence, in all further analyses, OPV1 as most recent vaccine is
grouped together no matter which vaccine the child had before
receiving OPV1, and the same applies to MMR.
Having OPV1 as the most recent vaccine was associated with a
signiﬁcantly lower rate of admission with any type of infection
compared with having DTaP-IPV-Hib3 as most recent vaccine
Table 1. Incidence Rate and Incidence Rate Ratio for Infectious Disease Hospital Admissions for the Most Recent Vaccine for Any Type of Infection (a),
Type of Infection (b), and Duration of Admission (c)
Outcomes and Most Recent Vaccine
Admissions per 100 Person-Years
(Admissions/Person-Years) Unadjusted IRRa (95% CI) Adjusted IRRb (95% CI)
(a) Any Type of Infection
DTaP-IPV-Hib3 7.2 (452/6243) 1 (ref) 1 (ref)
MMR 5.1 (1938/37 835) 0.72 (.65–.80) 0.86 (.77–.95)
OPV1 4.5 (4040/89 919) 0.65 (.59–.72) 0.85 (.77–.95)
MMR+OPV1 4.3 (83/1927) 0.64 (.51–.81) 0.76 (.60–.97)
(b) Type of Infectionc
Upper respiratory infections
DTaP-IPV-Hib3 2.8 (172/6243) 1 (ref) 1 (ref)
MMR 2.1 (785/37 835) 0.76 (.64–.90) 0.91 (.77–1.08)
OPV1 1.8 (1644/89 919) 0.72 (.61–.85) 0.93 (.79–1.10)
MMR+OPV1 1.5 (28/1927) 0.59 (.40–.89) 0.70 (.47–1.06)
Lower respiratory infections
DTaP-IPV-Hib3 2.7 (170/6243) 1 (ref) 1 (ref)
MMR 1.6 (618/37 835) 0.61 (.51–.72) 0.77 (.64–.92)
OPV1 1.3 (1157/89 919) 0.51 (.43–.61) 0.73 (.61–.87)
MMR+OPV1 1.5 (29/1927) 0.62 (.42–.92) 0.79 (.52–1.19)
Gastrointestinal infections
DTaP-IPV-Hib3 0.9 (58/6243) 1 (ref) 1 (ref)
MMR 0.7 (248/37 835) 0.78 (.58–1.04) 0.86 (.64–1.15)
OPV1 0.7 (650/89 919) 0.77 (.58–1.01) 0.89 (.67–1.18)
MMR+OPV1 0.7 (14/1927) 0.78 (.43–1.41) 0.87 (.48–1.58)
Other type infections
DTaP-IPV-Hib3 1.4 (86/6243) 1 (ref) 1 (ref)
MMR 1.2 (436/37 835) 0.80 (.64–1.02) 0.97 (.76–1.23)
OPV1 0.9 (828/89 919) 0.70 (.55–0.88) 0.94 (.74–1.20)
MMR+OPV1 0.8 (15/1927) 0.59 (.34–1.03) 0.69 (.39–1.21)
(c) Duration of Admission With Any Type of Infection
0 d
DTaP-IPV-Hib3 1.9 (117/6243) 1 (ref) 1 (ref)
MMR 1.5 (573/37 835) 0.81 (.66–.99) 0.98 (.79–1.21)
OPV1 1.3 (1131/89 919) 0.70 (.58–.86) 0.93 (.76–1.14)
MMR+OPV1 1.0 (19/1927) 0.58 (.36–.95) 0.73 (.45–1.20)
1 d
DTaP-IPV-Hib3 2.0 (127/6243) 1 (ref) 1 (ref)
MMR 1.6 (605/37 835) 0.80 (.66–.97) 0.93 (.76–1.13)
OPV1 1.5 (1306/89 919) 0.76 (.63–.92) 0.94 (.77–1.15)
MMR+OPV1 1.3 (26/1927) 0.71 (.46–1.09) 0.81 (.53–1.25)
2 d or more
DTaP-IPV-Hib3 3.3 (208/6243) 1 (ref) 1 (ref)
MMR 2.0 (760/37 835) 0.62 (.53–.72) 0.74 (.63–.88)
OPV1 1.8 (1603/89 919) 0.56 (.48–.65) 0.75 (.64–.88)
MMR+OPV1 2.0 (38/1927) 0.63 (.44–.90) 0.75 (.52–1.07)
Abbreviations: CI, confidence interval; DTaP-IPV-Hib, inactivated vaccine against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae type b; ICD-10, Tenth Revision of
the International Classification of Diseases; IRR, incidence rate ratio; MMR, live vaccine against measles, mumps, and rubella; OPV, live oral polio vaccine; ref, reference group.
a Cox proportional hazards model with age as underlying time and stratified by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for mother smoking during pregnancy, sex, birth weight, gestational age, caesarean section,
chronic diseases, number of infectious disease admissions before 24 months of age, admitted to hospital for any cause within the last 30 days, maternal age at birth of the child, highest
educational level for the female adult in the household, parental place of birth, adults in the household, income quintiles for the household, other children in the household, and population
density.
c The total number of admissions for the 4 types of admissions add to more than the total number of admissions, because admissions including ICD-10 codes frommore than 1 type of infection
were included in both groups.
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Table 2. Results for Interaction Between Most Recent Vaccine and Sex for Admissions due Any Type of Infection (a), Upper Respiratory Infections (b),
Lower Respiratory Infections (c), Gastrointestinal Infections (d), and Other Types of Infections (e)
Type of Infection, Sex, and Most Recent Vaccine
Admissions per 100 Person-Years
(Admissions/Person-Years) Unadjusted IRRa (95% CI) Adjusted IRRb (95% CI)
(a) Any Type of Infection
Female
DTaP-IPV-Hib3 5.8 (178/3043) 1 (ref) 1 (ref)
MMR 4.2 (777/18 511) 0.72 (.61–.85) 0.86 (.73–1.02)
OPV1 3.6 (1601/44 062) 0.65 (.56–.76) 0.83 (.71–.98)
MMR+OPV1 3.2 (29/893) 0.60 (.40–.89) 0.72 (.49–1.08)
Male
DTaP-IPV-Hib3 8.6 (274/3200) 1 (ref) 1 (ref)
MMR 6.0 (1161/19 325) 0.72 (.63–.82) 0.85 (.74–.98)
OPV1 5.3 (2439/45 857) 0.66 (.58–.75) 0.86 (.76–.99)
MMR+OPV1 5.2 (54/1034) 0.66 (.49–.88) 0.78 (.58–1.06)
P equality for MMR 0.918 0.917
P equality for OPV1 0.941 0.711
P equality for MMR+OPV1 0.709 0.748
(b) Upper Respiratory Infection
Female
DTaP-IPV-Hib3 2.1 (63/3043) 1 (ref) 1 (ref)
MMR 1.4 (262/18 511) 0.68 (.52–.90) 0.82 (.62–1.09)
OPV1 1.3 (572/44 062) 0.67 (.52–.88) 0.86 (.65–1.12)
MMR+OPV1 0.9 (8/893) 0.48 (.23–1.00) 0.59 (.28–1.24)
Male
DTaP-IPV-Hib3 3.4 (109/3200) 1 (ref) 1 (ref)
MMR 2.7 (523/19 325) 0.81 (.66–1.00) 0.97 (.78–1.20)
OPV1 2.3 (1072/45 857) 0.75 (.61–.92) 0.98 (.79–1.21)
MMR+OPV1 1.9 (20/1034) 0.65 (.40–1.05) 0.77 (.47–1.25)
P equality for MMR 0.315 0.376
P equality for OPV1 0.513 0.437
P equality for MMR+OPV1 0.496 0.562
(c) Lower Respiratory Infection
Female
DTaP-IPV-Hib3 2.0 (60/3043) 1 (ref) 1 (ref)
MMR 1.4 (257/18 511) 0.71 (.53–.94) 0.91 (.68–1.22)
OPV1 1.1 (465/44 062) 0.58 (.44–.77) 0.81 (.61–1.08)
MMR+OPV1 1.1 (10/893) 0.65 (.33–1.27) 0.83 (.42–1.64)
Male
DTaP-IPV-Hib3 3.4 (110/3200) 1 (ref) 1 (ref)
MMR 1.9 (361/19 325) 0.55 (.44–.68) 0.68 (.54–.86)
OPV1 1.5 (692/45 857) 0.48 (.39–.59) 0.68 (.55–.85)
MMR+OPV1 1.8 (19/1034) 0.59 (.36–.97) 0.76 (.46–1.27)
P equality for MMR 0.156 0.129
P equality for OPV1 0.257 0.333
P equality for MMR+OPV1 0.841 0.851
(d) Gastrointestinal Infection
Female
DTaP-IPV-Hib3 0.8 (25/3043) 1 (ref) 1 (ref)
MMR 0.6 (112/18 511) 0.81 (.52–1.25) 0.92 (.59–1.44)
OPV1 0.6 (280/44 062) 0.76 (.50–1.15) 0.90 (.59–1.37)
MMR+OPV1 0.7 (6/893) 0.81 (.33–1.99) 0.92 (.37–2.27)
Male
DTaP-IPV-Hib3 1.0 (33/3200) 1 (ref) 1 (ref)
MMR 0.7 (136/19 325) 0.76 (.52–1.12) 0.81 (.55–1.20)
OPV1 0.8 (370/45 857) 0.77 (.54–1.11) 0.88 (.61–1.28)
MMR+OPV1 0.8 (8/1034) 0.76 (.35–1.65) 0.84 (.38–1.83)
P equality for MMR 0.840 0.672
P equality for OPV1 0.956 0.953
P equality for MMR+OPV1 0.910 0.870
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(adjusted IRR, 0.85; 95% CI, .77–.95; Table 1a); this association
was strongest for admissions with lower respiratory infections
and for admissions lasting 2 days or more (Table 1b and c). The
association with admissions for lower respiratory infections was
found for all durations of admissions (Supplementary Table 2).
There were no statistically signiﬁcant differences in rates of admis-
sions for those having OPV1 as the most recent vaccine compared
with MMR (adjusted IRR, 0.99; 95% CI, .93–1.07) and MMR -
+OPV1 (adjusted IRR, 1.12; 95% CI, .90–1.39); this was also the
case when the data were analyzed for different types of admissions
and durations of admissions (data available on request).
An OPV1 as most recent vaccine was associated with an in-
signiﬁcant lower rate of admissions with otitis media compared
with having DTaP-IPV-Hib3 as the most recent vaccine (adjust-
ed IRR, 0.81; 95% CI, .60–1.08; Supplementary Table 3).
Additional Doses of Oral Polio Vaccine
The distribution of the different OPV doses was statistically sig-
niﬁcantly uneven for most background factors (Supplementary
Table 4). Compared with OPV1, having OPV2 or OPV3 as
most recent vaccine was associated with signiﬁcantly lower
rate of admissions with any type of infection for children
aged 36–60 months (adjusted IRR, 0.92; 95% CI, .86–.99; Sup-
plementary Results 1 and Supplementary Table 5).
Control Outcome: Emergency Department Visits After Unintentional
Injury
There was no association between the most recent vaccine and
the rate of emergency department visits after unintentional in-
jury (Supplementary Table 6 and Supplementary Table 5f ).
Interaction and Sensitivity Analyses
There was no statistically signiﬁcant interaction between most
recent vaccine and sex for any type of infection (Table 2).
None of the sensitivity analyses revealed any important differ-
ences from the main analysis (Supplementary Results 2).
DISCUSSION
The OPV1 was associated with a lower rate of admissions with
infection compared with DTaP-IPV-Hib as most recent vaccine,
mainly due to fewer admissions with lower respiratory infections
and admissions lasting 2 days or more. There were no signiﬁcant
differences between OPV1 and MMR as most recent vaccine.
We believe the reliability of the vaccination information is
high because it is reported by general practitioners for reim-
bursement purposes and control measures for overreporting
are in place [18], but we cannot exclude some underreporting
as found in a validation study of the Danish register-based vac-
cination information on DTaP-IPV booster vaccine [24]. Any
nondifferential misclassiﬁcation of vaccinations would bias
the estimates toward no association.
It is important to note that the analyses were performed in a
Cox regression with age as underlying time scale to secure com-
plete adjustment for age, because only children of the exact
same age are compared in this model. Furthermore, we adjusted
for a considerable number of other background factors, but re-
sidual confounding or confounding from unmeasured factors
cannot be excluded. A particular concern is healthy vaccinée
bias, ie, the most healthy children receive the next vaccine
ﬁrst, biasing the estimates toward lower rates of admissions
Table 2 continued.
Type of Infection, Sex, and Most Recent Vaccine
Admissions per 100 Person-Years
(Admissions/Person-Years) Unadjusted IRRa (95% CI) Adjusted IRRb (95% CI)
(e) Other Types of Infections
Female
DTaP-IPV-Hib3 1.3 (41/3043) 1 (ref) 1 (ref)
MMR 1.1 (207/18 511) 0.80 (.57–1.13) 0.92 (.65–1.31)
OPV1 0.9 (375/44 062) 0.66 (.48–.92) 0.84 (.60–1.18)
MMR+OPV1 0.7 (6/893) 0.53 (.22–1.25) 0.62 (.26–1.48)
Male
DTaP-IPV-Hib3 1.4 (45/3200) 1 (ref) 1 (ref)
MMR 1.2 (229/19 325) 0.81 (.58–1.11) 1.00 (.72–1.41)
OPV1 1.0 (453/45 857) 0.73 (.54–1.01) 1.03 (.74–1.43)
MMR+OPV1 0.9 (9/1034) 0.64 (.31–1.31) 0.76 (.36–1.58)
P equality for MMR 0.990 0.733
P equality for OPV1 0.649 0.390
P equality for MMR+OPV1 0.746 0.729
Abbreviations: CI, confidence interval; DTaP-IPV-Hib, inactivated vaccine against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae type b; IRR, incidence rate ratio;
MMR, live vaccine against measles, mumps, and rubella; OPV, live oral polio vaccine; ref, reference group.
a Cox proportional hazards model with age as underlying time scale and stratified by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for mother smoking during pregnancy, sex, birth weight, gestational age, caesarean section,
chronic diseases, number of infectious disease admissions before 24 months of age, admitted to hospital for any cause within the last 30 days, maternal age at birth of the child, highest
educational level for the female adult in the household, parental place of birth, adults in the household, income quintiles for the household, other children in the household, and population
density.
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for children who have received most vaccines. However, we did
not ﬁnd any indication of a lower rate of admissions with infec-
tion when OPV1 was given after MMR or vice versa (Figure 3).
This suggests that healthy vaccinée bias is an unlikely explana-
tion for the lower rate of admissions in children with OPV as
the most recent vaccine. In addition, if healthy vaccinée bias
was a major problem, the effect would probably be similar for
all types of infections and durations of admissions, which was
not the case in the present study. Furthermore, differences in
health-seeking behavior was unlikely to explain the results be-
cause there was no association between the most recent vaccine
and emergency department visits after unintentional injury.
The present study found that both MMR and OPV were asso-
ciated with less admissions for lower respiratory infection com-
pared with DTaP-IPV-Hib as most recent vaccine. We have
previously shown for children aged 11–24 months that compared
with DTaP-IPV-Hib as most recent vaccine, MMR was associated
with a 14% (95% CI, 12%–16%) lower rate of admissions with any
type of infection, the association being strongest for lower respira-
tory infection with a reduction of 20% (95% CI, 16%–24%) [14].
In the present study, most children with OPV as the most recent
vaccine had previously received MMR. This could suggest that the
apparent beneﬁcial nonspeciﬁc effect of OPV was in fact caused
by the previous MMR vaccination. However, OPV was also asso-
ciated with fewer admissions for lower respiratory infections com-
pared with DTaP-IPV-Hib as most recent vaccine among children
who had not yet received MMR (Supplementary Figure 1B).
One Finish open trial found that OPV compared with IPV
was associated with a lower risk of acute otitis media at 6–18
months of age [7]. We found a similar but not statistically sig-
niﬁcant association.
In low-income countries, there have been very few studies of
the association between OPV and child mortality because OPV
is nearly always given with other vaccines (BCG or DTP). How-
ever, 1 study from Guinea-Bissau showed that the case fatality at
the pediatric ward was signiﬁcantly reduced for children who,
due to shortage of DTP, had received OPV alone compared
with those children who had received the recommended combi-
nation of DTP and OPV [5]. Another study from Guinea-Bissau
showed that children below 6 months of age vaccinated with
OPV during a national immunization campaign had signiﬁcantly
lower mortality and lower rate of hospital admission within the
ﬁrst months after the campaign compared with those who did
not receive OPV [6]. Today, OPV is only used in low-income
countries, and the ﬁrst dose is recommended at birth together
with BCG. Previous observational studies have reported conﬂict-
ing results regarding the association between OPV at birth
(OPV0) and infant mortality [25, 26]. However, in the only ran-
domized trial, OPV0 administered with BCG at birth was associ-
ated with lower infant mortality than receiving BCG only (hazard
ratio, 0.68; 95% CI, .45–1.00) when the effect of subsequent OPV
campaigns was censored [27].
In previous studies of possible nonspeciﬁc effects of OPV, it
has been hypothesized that OPV could interfere with other en-
teroviruses [3, 4, 7, 8]. In this study, OPV was only statistically
signiﬁcantly associated to admissions with lower respiratory in-
fections and admissions lasting 2 days or more, which are likely
to be the most severe infections. These infections are probably
not related to enterovirus. Hence, the association between OPV
and these diseases indicate that other mechanisms might be
involved. Both changes in the adaptive immune responses to
unrelated pathogens after vaccination and trained innate immu-
nity have been suggested as mechanisms underlying nonspeciﬁc
effects of vaccines [12, 15], but this need to be further explored.
It would be particularly interesting to investigate mechanisms
that are related to lower respiratory infections because both
OPV, MMR, and MV have the strongest association with reduc-
tion in lower respiratory infections [8, 14, 28, 29].
The present study showed that the rate of admissions with in-
fections was similar for children who had OPV and MMR as the
most recent vaccine. The MMR vaccination is still included in
the vaccination program in Denmark. Because OPV1 was pri-
marily used after MMR, our study indicates that the phasing out
of OPV probably had only limited effects on overall morbidity
levels for children aged 24–36 months in the Danish popula-
tion. However, additional doses of OPV were associated with
lower rates of admissions with infections, and the second
dose of OPV was recommended at 3 years of age, so the mor-
bidity levels for children above 36 months of age might have
been affected by the phasing out of OPV.
CONCLUSION
Oral polio vaccine is associated with lower rate of admissions
with non-polio infections compared with DTaP-IPV-Hib as
most recent vaccine. The association was signiﬁcant for all ad-
missions, for admissions with lower respiratory infections, and
for admissions lasting 2 days or more. Hence, the phase-out of
OPV may affect morbidity levels, and it is important that the
potential beneﬁcial nonspeciﬁc effects of OPV be examined in
other studies to give a better basis for assessing the likely con-
sequences of stopping OPV globally.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseas-
es online (http://OpenForumInfectiousDiseases.oxfordjournals.org/)
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